Only five of 12 low- and middle-income countries had transition guidelines, according to a systemic review of adolescents living with HIV transitioning from paediatric to adult health care published in AIDS and Behavior.
The authors believe this to be the first review to survey the literature on barriers and facilitators of transition for adolescents living with HIV in low- and middle-income countries and to compare these factors to countries’ current guidelines.
Three models of same-day antiretroviral therapy (ART), tested in different hospitals in Thailand, are feasible and safe, researchers report. The models have been implemented in Thailand since 2017, following a World Health Organization recommendation that all individuals diagnosed as HIV positive should receive ART on the same day of diagnosis, if they are ready.
The U.S. Food and Drug Administration today approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. Descovy is not indicated in individuals at risk of HIV-1 infection from receptive vaginal sex because the effectivness in this population has not been evaluated.
ADM Brett Giroir, MD, Assistant Secretary for Health, recently spoke to the American Public Health Association (APHA) about Ending the HIV Epidemic: